Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study.

Wei-Jun WangZong-Han LiuKang WangHong-Ming YuYu-Qiang ChengYan-Jun XiangJin-Kai FengLi-Ping ZhouHong-Kun ZhouWei-Wei PanWei-Xing GuoJie ShiShu-Qun Cheng

Published in: Cancer medicine (2023)

T-L-P regimen was safe and superior to T-L or TACE alone in improving survival for unresectable recurrent HCC patients.

Keyphrases

end stage renal disease
ejection fraction
locally advanced
newly diagnosed
chronic kidney disease
squamous cell carcinoma
liver metastases
prognostic factors
patient reported outcomes
cross sectional
rectal cancer
patient reported